Utah Medical Products (UTMD) Common Equity (2016 - 2025)
Historic Common Equity for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $118.3 million.
- Utah Medical Products' Common Equity fell 478.68% to $118.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.3 million, marking a year-over-year decrease of 478.68%. This contributed to the annual value of $117.4 million for FY2024, which is 848.39% down from last year.
- As of Q3 2025, Utah Medical Products' Common Equity stood at $118.3 million, which was down 478.68% from $117.5 million recorded in Q2 2025.
- In the past 5 years, Utah Medical Products' Common Equity registered a high of $128.3 million during Q4 2023, and its lowest value of $104.9 million during Q1 2021.
- Over the past 5 years, Utah Medical Products' median Common Equity value was $117.4 million (recorded in 2024), while the average stood at $116.1 million.
- In the last 5 years, Utah Medical Products' Common Equity soared by 1434.2% in 2023 and then plummeted by 848.39% in 2024.
- Quarter analysis of 5 years shows Utah Medical Products' Common Equity stood at $107.1 million in 2021, then rose by 6.64% to $114.3 million in 2022, then grew by 12.3% to $128.3 million in 2023, then dropped by 8.48% to $117.4 million in 2024, then increased by 0.7% to $118.3 million in 2025.
- Its Common Equity stands at $118.3 million for Q3 2025, versus $117.5 million for Q2 2025 and $117.0 million for Q1 2025.